Article Per Year (5 Year)
p-Index From 2020 - 2025
0.444
P-Index
This Author published in this journals
All Journal Acta Interna : The Journal of Internal Medicine Journal of the Medical Sciences (Berkala Ilmu Kedokteran) Jurnal Farmasi Klinik Indonesia JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice) Majalah Farmaseutik Jurnal Farmasi
Kartika Widayati Taroeno Hariadi
Unknown Affiliation
Dentistry Health Professions Immunology & microbiology Medicine & Pharmacology Neuroscience Nursing Public Health

Published : 15 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 15 Documents
Search

 1   2 
Hubungan Penyakit Diabetes Melitus dan Penggunaan Antidiabetes terhadap Rekurensi pada Pasien Kanker Payudara Fitri Wulandari; Kartika Widayati; Fita Rahmawati
JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice) Vol 9, No 4
Publisher : Faculty of Pharmacy, Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (617.823 KB) | DOI: 10.22146/jmpf.48069

Abstract

Breast cancer is the cancer with the most prevalence of 43.3% and the mortality rate that reaches 12.9%. The prognosis of breast cancer can be affected by diabetes mellitus (DM), so that efforts to control DM through antidiabetic therapy are very necessary, but antidiabetic therapy is also reported to be associated with the prognosis of breast cancer. The purpose of this study was to determine the relationship of diabetes and antidiabetic use to recurrence in breast cancer patients. This study used a retrospective cohort design, involving 176 female non-metastatic breast cancer patients who received chemotherapy, consisting of 88 patients with DM and 88 non-DM patients. The exposures in the study were diabetes mellitus and the types of antidiabetic drugs (metformin and non metformin based therapy), while the study output was the recurrence of breast cancer. The research data was obtained from the patient’s medical records at RSUP Dr. Sardjito Yogyakarta. Research analysis used Chi-square, Kaplan Meier method and Cox-regression to estimate Hazard Ratio with 95% confidence interval. The results showed DM in breast cancer patients was associated with increased the risk of recurrence (HR 2,458; 95% CI 1,571-3,846, log rank test P=0,000), while the use of antidiabetic types (metformin and nonmetformin) to control DM in breast cancer patients was not associated with the risk of recurrence (HR 1.391; 95% CI 0.816 - 2.370, log rank test P=0.210). Further research is warranted by monitoring blood glucose levels regularly.
The Effectiveness of Zoledronic Acid and Ibandronic Acid in Delaying Skeletal-Related Events in Multiple Myeloma in Indonesia Nutrisia Aquariushinta Sayuti; Tri Murti Andayani; Dwi Endarti; Kartika Widayati
JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice) Vol 10, No 3
Publisher : Faculty of Pharmacy, Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/jmpf.55943

Abstract

Zoledronic acid and ibandronic acid are listed in the Indonesian national formulary to prevent skeletal-related events (SRE) in patients diagnosed with bone metastasis in multiple myeloma (MM), with limited evidence to compare their effectiveness. This study aimed to investigate the effectiveness and safety of zoledronic acid and ibandronic acid in delaying SRE. The method was the retrospective, with data obtained from the multicenter study for MM patients with bone metastasis (aged over 18 years), based on medical records between January 2016 and December 2018. Patients were assigned to zoledronic acid and ibandronic acid groups. The clinical outcome was the next SRE which consists of vertebral/bone fracture, spinal cord compression leading to the need for surgery or radiation, and adverse event (AE) due to 2 years of drugs usage. Result of this research was made up of a total of seventy (70) patients with  40  in the zoledronic acid group, and 30 in ibandronic acid. At median treatment duration of 8 months (range: 2 – 24 month), SRE incident in zoledronic acid and ibandronic acid were 20.0 % and 23.3 % respectively. Furthermore, their mean SRE free survival times were 21 months [95% confidence interval (CI) 19 - 23 months], and 19 months [95% CI, 16 – 22 months], respectively. Also, their time intervals were not significantly different (p>0.05). The osteonecrosis of the jaw (ONJ) was AE which occurred more in zoledronic acid than ibandronic acid. The conclusion was zoledronic acid tends to delay SRE time compared to ibandronic acid, although more ONJ occur.
Hubungan Penggunaan Antihipertensi Terhadap Rekurensi pada Pasien Kanker Payudara non Metastasis Widyaningrum Utami; Kartika Widayati; Fita Rahmawati
Majalah Farmaseutik Vol 16, No 2 (2020)
Publisher : Faculty of Pharmacy, Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (371.558 KB) | DOI: 10.22146/farmaseutik.v16i2.48603

Abstract

Hipertensi merupakan jenis komorbid yang sering terjadi pada pasien kanker payudara. Beberapa penelitian sebelumnya menunjukan adanya hubungan antara antihipertensi terhadap kekambuhan (rekurensi) pasien kanker payudara, namun hasilnya belum konsisten. Tujuan penelitian untuk mengetahui hubungan antara penggunaan antihipertensi terhadap kejadian atau waktu rekurensi pada pasien kanker payudara.Penelitian menggunakan desain cohort resrosppective dengan melibatkan pasien sejumlah 120 penderita kanker payudara non metastasis terbagi menjadi dua kelompok yaitu kelompok yang menggunakan antihipertensi (60 pasien) dan kelompok yang tidak menggunakan antihipertensi (60 pasien) yang memenuhi kriteria inklusi di RSUP Dr. Sardjito, Yogyakarta. Sumber data penelitian diperoleh dari rekam medik pasien tahun 2015 sampai 2018. Hubungan antara antihipertensi terhadap rekurensi dianalisis menggunakan Chi-square kemudian dilanjutkan dengan analisis survival dengan Kaplan-Meier dan cox-regresion. Waktu terjadinya rekurensi ditentukan dari waktu antara diagnosis dengan saat terjadinya sel kanker payudara yang tumbuh kembali. Hasil penelitian menunjukkan tidak terdapat hubungan antara obat antihipertensi dengan kejadian rekurensi pada pasien kanker payudara (HR 1.341; 95%CI 0.632-2.848, log rank test P=0.444). Begitu pula dengan jenis obat antihipertensi (ARB, CCB dan kombinasi keduanya) juga tidak berhubungan dengan kejadian rekurensi (p=0.279). Namun terdapat perbedaan mean recurrence time yaitu 40 bulan pada pasien kanker payudara dengan antihipertensi ARB tunggal (HR=1.427; 95%CI=0.527-3.859), 57 bulan dengan antihipertensi CCB tunggal (HR=0.696; 95%CI=0.257-1.884), dan 58.65 bulan dengan antihipertensi kombinasi.
The Effect of Weight Gain on Recurrence During Hormonal Therapy in Breast Cancer with Positive Estrogen Receptor and Negative Her2 Subtype Nugraha, Doddy Rizqi; Taroeno-Hariadi, Kartika Widayati; Hardianti, Mardiah Suci
Acta Interna The Journal of Internal Medicine Vol 11, No 1 (2021): Acta Interna The Journal of Internal Medicine
Publisher : Faculty of Medicine Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/actainterna.94634

Abstract

Background. Weight gain is found in patients with positive estrogen subtype breast cancer. The effect of weight gain on breast cancer recurrence is still being debated and associated with a poor prognosis. Being overweight is associated with an increase in estrogen production by adipose tissue.Methods. A retrospective and prospective cohort study with data collection was conducted from July 2018 - June 2019 at the outpatient unit of Dr. Sardjito Hospital. We reviewed medical records of patients who came from January 2013 - July 2018.  Three categories of weight gain:  weight loss, increase 0 - 5%, and increase > 5% from baseline will be evaluated.Statistical Analysis. The relationship between weight gain and some risk factors of recurrence was analyzed with cox regression and multivariate logistic regression tests. The Kaplan Meier method is used to show lifetime data.Result. Weight gain in breast cancer patients with positive Her2-negative estrogen receptor subtypes was not associated with recurrence (p = 0.264; HR 0.637; 95% CI 0.289 - 1.405). Patients with body mass index ≥ 25 kg / m2 at diagnosis had a lower risk of relapse than patients with body mass index < 25 kg / m2 (p = 0.026; HR 0.461; 95% CI, 0.234 - 0.912).Conclusions Weight gain after diagnosis in breast cancer patients with positive estrogen receptor-negative Her2 subtypes receiving hormonal therapy is not associated with recurrence.
Perbandingan Efektivitas Produk Filgrastim pada Pasien Keganasan Limfoma yang Menerima Kemoterapi di RSUP dr. Sardjito Yogyakarta Setiani, Dhien; Ikawati, Zulies; Widayati, Kartika
Jurnal Farmasi (Journal of Pharmacy) Vol. 4 No. 1 (2015): Jurnal Farmasi (Journal of Pharmacy), October 2015
Publisher : Jurnal Farmasi (Journal of Pharmacy)

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Neutropenia is a common toxicity in cancer patients receiving chemotherapy myelotoxic as lymphoma result. Granulocyte Colony Stimulating Factor (G-CSF) is clinically recommended for neutropenia. Filgrastim is a generic name of the brand G - CSF products circulating in Indonesia such as Filgrastim brand A and brand B produced by a different manufacturer. The differences Filgrastim brand A and brand B produced by non-factory is that Filgrastim A product’s price is cheaper than brand B. Comparison of the effectiveness of Filgrastim brand A and brand B in patients at DR.Sardjito Hospital Yogyakarta need to be examined to evaluate the effectiveness of the type of drugs has been clinically used. The purpose of this study was to compare the effectiveness of Filgrastim A and B on the use of daily clinical practice at RSUP Dr. Sardjito Yogyakarta. The design of this study is analytic retrospective cohort study that is applied for patients receiving chemotherapy in cancer Installation Tulip Hospital Dr. Sardjito. Data was retrieved from medical records the period January 2013 to March 2015. Comparison of the effectiveness of filgrastim uses the parameter of time to reach the Absolute Neutrophil Count (ANC) recovery. Data of characteristics subjects were analyzed by using chi square Goodness of Fit for categorical data and independent t test for numerical data. The comparison of effectiveness of filgrastim was analyzed by using survival analysis. A total of the study showed that there were 80 subjects which consists of 192 episodes of neutropenia incidence of filgrastim therapy. From 80 subjects, there were 43 subjects ( 53,5 % ) which consist of 72 episodes of neutropenic (33 episodes with filgrastim brand A and 39 episodes with filgrastim brand B) that met the inclusion criteria. The result of the comparison of filgrastim effectiveness based on time to ANC recovery, according to the bivariate Kaplan-Meier with the laboratory observation data 24 hours post last injections, it shows that Filgrastim brand A has a median recovery time faster than Filgrastim brand B (1,00 vs 2,00 p< 0,05). The conclusions of this study , in the ANC recovery time, Filgrastim brand A more effective than Filgrastim brand B.
Co-Authors Diah Ari Safitri Dwi Wulansih Fef Rukminingsih Fita Rahmawati Fita Rahmawati Fitri Wulandari Fitri Wulandari Ibnu Purwanto Johan Kurnianda Mardiah Suci Hardianti Nugraha, Doddy Rizqi Nutrisia Aquariushinta Sayuti, Nutrisia Aquariushinta Prafita Cahya Dewanti Rahmawati, Fita Rukminingsih, Fef Setiani, Dhien Tri M. Andayani Tri Murti Andayani Tri Murti Andayani Tri Murti Andayani Widyaningrum Utami Zulies Ikawati, Zulies